Sanofi is buying Vicebio, a biotech, that is developing vaccines for two viruses using the molecular clamp technology ...

The acquisition, which will give Sanofi a combination vaccine for respiratory syncytial virus and human metapneumovirus, ...

The deal complements an existing partnership with Novavax that encompasses R&D of combination vaccines for Covid-19 and flu.

PARIS] Sanofi agreed to buy UK biotech Vicebio for as much as US$1.6 billion, gaining experimental vaccines and a technology ...

Earlier this summer the FDA asked Moderna for more efficacy data on its flu vaccine before it could review an mRNA-based ...

“Vicebio’s Molecular Clamp technology introduces a purposefully simple but thoughtful approach to further improve vaccine ...

Sanofi said May 17 it will soon launch a late-stage trial for the COVID-19 vaccine it is developing with GlaxoSmithKline after the vaccine produced a strong immune response in phase 2 trial ...

Sanofi and GlaxoSmithKline said Oct. 28 that they will provide 200 million doses of their COVID-19 vaccine to the World Health Organization's Covax initiative if the vaccine receives regulatory ...

PARIS, May 14 (Reuters) - Sanofi chief executive Paul Hudson said on Thursday it was vital that any coronavirus vaccine reach all parts of the world, after angering the French government earlier ...

Britain is close to a 500 million pound ($624 million) supply deal with Sanofi and GlaxoSmithKline for 60 million doses of a potential COVID-19 vaccine, the Sunday Times reported.

LONDON (AP) — Drugmakers Sanofi and GlaxoSmithKline said Friday that their potential COVID-19 vaccine won’t be ready until late next year because they need to improve the shot’s ...